

The Introduction of the Bio-pharmaceutical Industry in Ningbo City

Under the strategic deployment of the Ningbo Committee of the Communist Party of China and the People's Government of Ningbo Municipality, the bio-pharmaceutical industry has been elevated to a priority sector within the modern healthcare industry and incorporated into the overall nurturing plan for the "361" industrial clusters (by 2027, Ningbo plans to cultivate and form 3 trillion-level industrial clusters, 6 billion-level industrial clusters and 1 batch of rising and future industrial clusters). This plan primarily encompasses three domains: bio-pharmaceuticals, medical devices, and sports and cultural supplies. In 2023, Ningbo's modern healthcare industry boasted 496 enterprises above a designated size, generating a total industrial output value of 74.2 billion RMB. Among these, the bio-pharmaceutical sector included 64 enterprises, achieving a total industrial output value of 11.29 billion RMB, with a year-on-year decrease of 3.7%; the medical device sector comprised 66 enterprises, with a total industrial output value of 5.99 billion RMB and a year-on-year increase of 3.3%. The pharmaceutical and medical device sectors together host 1 national champion enterprise in one area, 10 national specialized and sophisticated enterprises that produce new and unique products, 7

listed companies, and 4 large-sized leading enterprises.

1. Accelerated Formation of Industrial Agglomeration: After years of development, the city's bio-pharmaceutical industry has initially formed a spatial layout led by "three parks" and supported by "three areas". The "Qianwan New District Life Health Industrial Park, Ningbo Biomedical Park (Ninghai), and Meishan Life Health Industrial Park" focus on pharmaceutical R&D and industrialization, public technology platforms, and high-end medical devices. "The central urban area of Haishu, Jiangbei, Yinzhou , the area of Zhenhai, Beilun, and the area of Yuyao, Cixi" focus on the development of diagnostic reagents, innovative drugs, and high-value medical devices and consumables.

2. Rapid Development in Sub-sectors: Rong'an Biological's rabies vaccine for human use has captured 25% of the market share; Zhengli Packaging holds nearly 85% of the vaccine packaging material market share; Xingaoyi Medical Equipment Co., Ltd. and Acrostar's sales of radiological medical devices rank 5th and 6th globally, respectively; Ningbo Jansen Superconducting Technologies Co., Ltd's "1.5T helium-free superconducting magnet system" became the first set (suite) product in Ningbo and in the world; Ningbo David Medical Device Co., Ltd. holds the world's number

one market share in infant incubators; Zhejiang Guangci Medical Equipment Co., Ltd's "ZDI artificial dental implant" was recognized as an industrial demonstration project under the Ministry of Science and Technology's China Torch Program; Jenscare Scientific Co., Ltd.'s transcatheter tricuspid valve replacement system is internationally leading.

3. Significant Achievements in Key Project Introduction and Cultivation: By the end of 2023, there were 26 ongoing projects in the bio-pharmaceutical industry with an investment over 100 million yuan respectively, with a planned total investment of 19.96 billion yuan. Among these, the Health BioMed IVD Industrial Park project is planned to use about 200 mu (\approx 13.34 hectares) of land; the Pharmaron's three major bases project; among the 23 projects in Linfeng Medical Technology Industrial Park, 13 of them have entered substantive operation, including Jenscare Scientific Co., Ltd., SensCure, Ningbo HICREN Biotechnology Co., Ltd., and other enterprises in the park, with valuations exceeding 10 billion yuan.